MNKD: MannKind Corp. Kompaniya qiymatining sof foydaga nisbati

MannKind Corp (MNKD) korporativ emblemasi va logotipi

Inhalatsiya orqali qabul qilinadigan diabet terapiyasiga bo'lgan talabning ortishi MannKind Corporation (MNKD) iste'molchilari bazasini kengaytirmoqda. Kompaniyaning foyda ko'rsatkichi biznesning baholanish tendentsiyasini aks ettiradi, bunda -18.00 joriy metrika hisoblanadi. Biroq, geosiyosiy risklar va sanksiyalar bir qator bozorlarga kirishni cheklamoqda. Ta'minot barqarorligi Connecticut shtatidagi o'zining yuqori texnologik zavodi tomonidan ta'minlanadi, bu esa sterillik va ishlab chiqarishning to'liq nazoratini kafolatlaydi.

MNKD Afrezza: Narx-foyda koeffitsiyenti 04.07.2022 - 15.11.2026 oraligʻida

MannKind Corp (MNKD) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning har tomonlama tahlili:MannKind Corp - MNKD
MannKind yetakchi tovari

MannKind Corporation (MNKD) inhalatsiya tizimlari ta'minot zanjiri boshqaruvining samaradorligi kompaniyaning joriy bozor kapitalizatsiyasini sof foyda bilan solishtiruvchi P/E grafigida bevosita aks etgan. Ushbu koeffitsiyentni tahlil qilish aktivning premiumini aniqlash imkonini beradi va joriy daromadlilik hamda uzoq muddatli yetkazib beruvchilar bilan tuzilgan shartnomalarning barqarorligi saqlanib qolgan holda, investitsiyalar return on investment ko'rsatkichiga yetishi uchun necha yil kerak bo'lishini baholash imkonini beradi.

Raqobatdosh kompaniyalar tahlili

HLN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Jyong Biotech Limited MENS|Ligand (LGND) - Kapitalizatsiyaning foydaga nisbati|AMRX: Narx-foyda koeffitsiyenti|Perrigo - Bozor narxining sof foydaga nisbati|ALVO: P/E multiplikatori|Liquidia Technologies - Kompaniya qiymatining sof foydaga nisbati|GLPG (Galapagos N.V.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati anipharmaceuticals.com ANIP|Narxning foydaga nisbati Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SPRY (ARS Pharmaceuticals Inc)|Bozor narxining sof foydaga nisbati TBPH (Theravance)|AQST - Narxning foydaga nisbati|scPharmaceuticals (SCPH) - Narx-foyda koeffitsiyenti|TECX: P/E multiplikatori|Narx-foyda multiplikatori TNXP|Narxning foydaga nisbati China SXT Pharmaceuticals, Inc.|EPRX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori BHST|EXOZ - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ORMP (oramed.com)|P/E multiplikatori enterabio.com ENTX|HYFT - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati ABVC BioPharma, Inc ABVC|CPIX: P/E multiplikatori|Quantum BioPharma Ltd - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti FGEN|Telomir Pharmaceuticals, Inc. - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori RANI|SNYR (Synergy CHC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Rallybio RLYB|Lexaria Bioscience (LEXX) - Kapitalizatsiyaning foydaga nisbati|PULM - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pheton Holdings PTHL|APM (Aptorum) - Narx-foyda koeffitsiyenti|Lyra Therapeutics, Inc. (LYRA) - P/E multiplikatori|IBO (impactbiomedinc.com) - P/E multiplikatori|TNFA (TNF Pharmaceuticals) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati cbdmd.com (YCBD)|Biznesning o‘zini qoplash muddati PainReform Ltd|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Kapitalizatsiyaning foydaga nisbati|OPTN - Narxning foydaga nisbati|Pieris Pharmaceuticals - Bozor narxining sof foydaga nisbati|PROC (Procaps Group) - Narx-foyda koeffitsiyenti|PTPI - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qilian International Holding Group Limited|SLRN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TFFP (TFF Pharma)